Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358 · View on ClinicalTrials.gov ↗

Study Summary

COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.

Interventions

  • PROCEDURE Physiology-guided NCL PCI
  • PROCEDURE Angiography-guided NCL PCI

Study Locations (20)

Other

  • Klinik Floridsdorf — Vienna
  • William Osler Health System — Brampton
  • University of Alberta Hospital, Mazankowski Heart — Edmonton
  • Hamilton Health Sciences — Hamilton
  • Kingston Health Sciences Centre — Kingston

New York

  • Bassett Medical Center — Cooperstown
  • VA New York Harbor HealthCare System — New York
  • NYU Grossman School of Medicine — New York
  • Montefiore Medical Center — The Bronx

California

  • UCLA — Los Angeles
  • University of California, San Francisco — San Francisco

Kansas

  • Cardiovascular Research Institute of Kansas — Wichita

Maryland

  • The Johns Hopkins University School of Medicine — Baltimore

Michigan

  • University of Michigan — Ann Arbor

Minnesota

  • Metropolitan Cardiology Consultants / Metropolitan Heart and Vascular Institute (MCC/MHVI) — Coon Rapids

New Jersey

  • RWJ Barnabas Health — Jersey City

Trial Details

FieldValue
Enrollment Target 5,100 participants
Start Date 2023-06-22
Est. Completion 2028-06
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05701358

The ClinicalTrials.gov registry entry for NCT05701358 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Health Research Institute, which has 68 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions — of which Physiology-guided NCL PCI is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05701358 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05701358 about?

NCT05701358 is a clinical study titled "Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease". COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardia...

What is the current status of trial NCT05701358?

This trial is currently recruiting. It is a NA study. The enrollment target is 5,100 participants. The study started on 2023-06-22. Estimated completion is 2028-06.

What conditions does trial NCT05701358 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Acute Myocardial Infarction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05701358?

The interventions under investigation include: Physiology-guided NCL PCI (PROCEDURE), Angiography-guided NCL PCI (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05701358?

This trial is sponsored by Population Health Research Institute, which has 68 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05701358 being conducted?

This trial has 20 study locations across California, Kansas, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial